An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity and Hyperuricemia, sponsored by Ningbo No. 1 Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Ningbo No. 1 Hospital · Observational
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.
27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.
This study's planned enrollment of 17,040 is above the median of 134 across 10 observational studies indexed under Obesity, Metabolically Benign.
Browse Obesity, Metabolically Benign studies →Ningbo No. 1 Hospital is the lead sponsor of 59 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This cohort study included participants who underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024. A total of 18,261 individuals aged 18 years or older who completed abdominal ultrasound examinations were initially considered. After excluding underweight individuals (BMI \< 18.5 kg/m²; N = 1,138) and those with missing data on height, weight, or metabolic syndrome (MetS) components (N = 83), 17,040 participants remained eligible for further analysis.For the MASLD incidence analysis, individuals with a baseline diagnosis of MASLD or other liver diseases (N = 5,328) were excluded, resulting in 11,712 participants. For the hyperuricemia incidence analysis, those with baseline hyperuricemia (N = 3,194) were further excluded, yielding 13,846 eligible participants. During a median follow-up period of up to 7 years, 3,756 incident cases of MASLD and 3,294 incident cases of hyperuricemia were
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants with non-MASLD at baseline
participants with non-Hyperuricemia at baseline
Incidence of MASLD and Hyperuricemia
through study completion
Time frame: 7 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obesity, Metabolically Benign →
Ningbo No. 1 Hospital